NCT04392037 - Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 17, 2021

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Multiple Myeloma

Interventions

DRUG

Iberdomide plus low-dose cyclophosphamide and dexamethasone

Iberdomide, low dose Cyclophosphamide and Dexamethason will be given until progression or unacceptable toxicity

Trial Locations (9)

NWZ, Alkmaar

Amsterdam UMC, location AMC, Amsterdam

Amsterdam UMC, location VUmc, Amsterdam

Rijnstate, Arnhem

Amphia Ziekenhuis, Breda

Albert Schweitzer Ziekenhuis, Dordrecht

UMC Groningen, Groningen

Antonius ziekenhuis, Nieuwegein

Radboud UMC, Nijmegen